## Electronic Supplementary Information

## A Small Peptide Stereochemically Customized as a Globular Fold with a Molecular Cleft $\dagger$

Soumendra Rana, ${ }^{\text {a }}$ Bijoy Kundu, ${ }^{\text {b }}$ and Susheel Durani ${ }^{\text {a* }}$<br>Department of Chemistry, ${ }^{\text {a }}$ Indian Institute of Technology Bombay, Mumbai-400076 and Medicinal Chemistry Division, ${ }^{\text {b }}$ Central Drug Research Institute, Lucknow-226001, India.

## Sequence Design and Validation

The sequence design was approached rationally selecting $\beta$-sheet favoring amino acid residues to obtain a heterogeneous sequence for the ease of experimental validation by spectroscopic techniques like NMR and Fluorescence but of amphipathic character to achieve a fold with a $\mathrm{H}_{2} \mathrm{O}$ exposed hydrophilic exterior and a non-polar interior topology. The core of the design approach is guided by the fundamental stereospecificity of folding in polypeptides, as captured in the Ramachandran diagram. The positions for stereochemical inversions from L-to-D in the sequence were so chosen to obtain an amphipathic kind of molecular fold with a hydrophobic core and a surface largely composed of hydrophilic residues, illustrated in Figure $\mathrm{S}-1, \mathrm{C}$. The residues $\operatorname{Thr}(8)-\operatorname{Ser}(13), \operatorname{Asn}(15)-\operatorname{Ser}(6)$, and Lys(17)-Glu(4) were positioned as the cross-strand neighbors to obtain inter-strand locking required for a stable $\beta$-hairpin kind of motif. The conformational ordering of our designed sequence was validated by MD against "Trp-cage" (PDB code $=1 \mathrm{~L} 2 \mathrm{Y}$, Figure S-2, B), a recently reported globular mini-protein, achieved by rational design of comparable polypeptide length. ${ }^{5}$ Parallel unrestrained MD simulations in explicit $\mathrm{H}_{2} \mathrm{O}$ for 2 ns at 300 K performed under identical conditions, reflected favorably on the promise of our designed heterotactic peptide (Figure S-2, A) as a protein compared with the simulated properties of the "Trp-cage", providing the confidence for experimental validation of the design based on synthesis and spectroscopic characterization.

## Experimental Section

All amino acids with suitable protecting groups were purchased from Novobiochem (Switzerland). The 20 -residue peptide was synthesized manually in a 10 ml syringe by standard solid phase Fmoc-chemistry with TBTU / HOBT or HOBT / DIC method with Rink Amide AM resin as the solid support, at a $0.74 \mathrm{mMol} / \mathrm{gm}$ scale. The resin was deblocked at the N -terminus by $30 \%$ Piperidine-DMF with continuous shaking for 0.5 hours. Kaiser and ninhydrin tests were used for monitoring the completion of coupling or de-blocking of amino groups. The N -terminus was capped
by acetylation $\left(-\mathrm{NCOCH}_{3}\right)$ using $\mathrm{Ac}_{2} \mathrm{O}$ : DIPEA: DMF in a ratio of 1:2:20 for 5 hours. The final peptide was obtained as a primary amide group $\left(-\mathrm{CONH}_{2}\right)$ at C-terminus. Simultaneous cleavage of the peptide from the resin bed and deprotection of side-chains were achieved with reagent-K [TFA: $\mathrm{H}_{2} \mathrm{O}$ : Phenol: Thioanisole: EDT in a ratio of 82.5:5:5:5:2.5] over 1.5-4.0 hours at room temperature with continuous shaking. After removal of TFA by passing $\mathrm{N}_{2}$ gas, the peptide was precipitated with cold diethyl ether (anhydrous), lyophilized and then purified by HPLC over RP-18 silica column $\left(10 \mu \mathrm{~m}, 10 \mathrm{~mm} \times 250 \mathrm{~mm}\right.$; Merck) using $\mathrm{ACN} \backslash \mathrm{H}_{2} \mathrm{O} \backslash 0.1 \% \mathrm{TFA} \backslash 0-100 \%$ gradient. The homogeneity was checked on a RP-18e silica analytical column ( $5 \mu \mathrm{~m}, 4 \mathrm{~mm} \times 250 \mathrm{~mm}$; Merck) using the above eluents. The presence of the desired peptide was confirmed by MALDI-TOF Mass spectrometry (Mcalc: $2157 \mathrm{Da} ; \mathrm{M}_{\mathrm{obs}}: 2158 \mathrm{Da}$; and $\mathrm{M}_{\mathrm{Na}+}: 2180 \mathrm{Da}$, which confirmed that methionine sulphur is not oxidized) and subsequently by ${ }^{1} \mathrm{H}$ NMR analysis. Two sets of ${ }^{1} \mathrm{H}$ NMR spectra recorded in $\mathrm{H}_{2} \mathrm{O}$ at 2.5 mM and 0.25 mM concentration did not show any significant changes in chemical shifts or in sharpness of the resonances, evidencing absence of aggregation. Concentration dependent CD measurements were recorded at 298 K in $0.5 \mathrm{mM} \mathrm{CH}_{3} \mathrm{CO}_{2} \mathrm{Na}$ buffer at $\mathrm{pH} \cong 5$. No significant change in molar ellipticity was observed for the peptide in the $40 \mu \mathrm{M}$ to $100 \mu \mathrm{M}$ concentration range, suggesting the absence of aggregation. The peptide concentration was determined using molar extinction coefficient of $\operatorname{Trp}(\sim 5600$ at 278 nm$)$. Spectra were recorded in Far UV region on a JASCO J-810 CD spectroploarimeter equipped with a peltier controller [0.2cm quartz cell, $700 \mu \mathrm{l}$ volume, scanning rate of $100 \mathrm{~nm} / \mathrm{min}$, time constant 1.0 s ] over an average of 5 accumulations with step resolution of 0.5 nm , and bandwidth of 2 nm . Phase sensitive TOCSY (mixing time $80 \mathrm{~ms}, 32 \mathrm{scans}$, 480 experiments) and NOESY (mixing time $200 \mathrm{~ms}, 48$ scans, 480 experiments) spectra were recorded at 298 K in pure ${ }^{2} \mathrm{H}_{2} \mathrm{O}$ or $90 \% \mathrm{H}_{2} \mathrm{O} / 10 \%{ }^{2} \mathrm{H}_{2} \mathrm{O}$ for the peptide $\cong 2-3 \mathrm{mM}$ concentration at $\mathrm{pH} \cong 5$ on a VARIAN INOVA 600 MHz NMR. A 0.1 mM concentration of 3-(trimethyl-silyl)-1propanesulfonicacid (DSS) was used for an internal chemical shift reference. Solvent suppression in $\mathrm{H}_{2} \mathrm{O}$ was achieved either by presaturation or by WATERGATE pulse sequence provided by VARIAN. The data processing was done on a SGI workstation equipped with VNMR and XWIN-NMR or on a windows workstation equipped with FELIX software. Typically a sine-squared window function, phase shifted by $70^{\circ}$ was applied in both dimensions with the data zero filled to $2 \mathrm{~K} \times 1 \mathrm{~K}$ or else $4 \mathrm{~K} \times$ 4 K points before Fourier transformation. The fluorescence measurements were on a Perkin Elmer LS55 spectrofluorimeter equipped with a standard PMT, properly stabilized and after base line corrections over a single accumulation in $20 \mathrm{mM} \mathrm{CH}_{3} \mathrm{CO}_{2} \mathrm{Na}$ buffer, $\mathrm{pH} \cong 5\left[1 \mathrm{ml}\right.$ cell, $\lambda_{\text {excitation }}=295$ $\mathrm{nm}, \lambda_{\text {emission }}=297-450$, excitation and emission slits $=3 \mathrm{~nm}$, scan speed $=100 \mathrm{~nm} / \mathrm{min}$ ] at room
temperature. The working concentration $(20 \mu \mathrm{M})$ of the HPLC purified peptide and NATA (SIGMA chemicals) was calibrated by OD measurements using molar extinction coefficient of $\operatorname{Trp}$ ( $\sim 5600$ at 278 nm ). All the quenching experiments involving KI and Methionine were performed in the above said manner with suitable quencher concentration adjusted by dilution of stock solution of molar concentration. The initial coordinates of the peptide were energy minimized both in vacuum and in $\mathrm{H}_{2} \mathrm{O}$ for 2000 steps using steepest descent algorithm. The molecule was kept at 300 K in the center of a cubic box in explicit solvent for 100ps for achievement of thermal equilibration followed by production MD run. All MD simulations were performed on P-IV linux platform using gromos-96 force field in the GROMACS package.

Figure S-1. A) The 20-residue isotactic model sequence. The six-long arm hydrophobic residues (side-chains shown in CPK) are far apart from each other, featuring a planar canonical $\beta$-hairpin morphology. The residues for stereochemical inversions from L-to-D (side-chains shown in ball and stick) are in blue. B) The $\beta$-hairpin after the first pair $(7,14)$ of stereochemical inversion. C) The $\beta$ hairpin after the second pair $(3,18)$ of stereochemical inversion, resulting in a 20 -residue quasiglobular mini-protein with six-long arm hydrophobic residues (side-chains shown in CPK) forming a hydrophobic core and a largely hydrophilic surface. The stereochemical inversions from L-to-D (sidechains shown in blue ball and stick) has resulted in engineering the flat $\beta$-hairpin to a potential boat shaped molecular cleft, creating a scope for diversified functional design.

Figure S-2. A) Snapshots of molecular cleft taken from MD trajectory at an interval of 500 ps . B) Snapshots of "Trp-cage" taken from MD trajectory at an interval of 500ps.

Figure S-3. Summary of the results obtained from the 2 ns MD simulations at 300 K . A) Trp-cage. B) Molecular Cleft. C) Total number of hydrogen bonds populated over the trajectory. $\mathrm{R}_{\text {peptide }}=$ radius of gyration of the peptide, $\mathrm{R}_{\text {core }}=$ radius of gyration defined by residues forming the hydrophobic core and C -alpha $=$ RMSD of $\mathrm{C}_{\alpha}$ atoms.

Figure S-4. MALDI-MS and analytical HPLC profile of boat shaped peptide molecular cleft.
Figure S-5. Concentration dependent mean residue ellipticity of the peptide in $\mathrm{H}_{2} \mathrm{O}$ at 298 K .
Figure S-6. The blurrogram of 10 best DYANA generated NMR structures are with mean global backbone root mean square deviation (RMSD) over residue 2-19 of $0.39 \pm 0.24 \AA$ and mean global all heavy atoms RMSD of $1.11 \pm 0.28 \AA$ in $\mathrm{H}_{2} \mathrm{O}$.

Figure S-7. The average number of hydrogen bonds populated in $\mathrm{H}_{2} \mathrm{O}$ over the MD trajectory of 16 ns is 8 compared with 9 hydrogen bonds expected in the ideal boat shaped peptide motif. The
calculation was done in explicit solvent using gromos-96 force field in GROMACS 3-1 package in a cubic box at 300 K .

Figure S-8. Plot of potential energy of the boat shaped peptide molecular cleft against time over the MD trajectory in $\mathrm{H}_{2} \mathrm{O}$.

Figure S-9. Time dependent proximity plot of $\mathrm{C}^{\beta}$ atoms of the core forming residues $[$ Rcore $4=$ $\operatorname{Leu}(16), \operatorname{Trp}(5), \operatorname{Leu}(20)$ and $\operatorname{Met}(1)$ and $\operatorname{Rcore6}=\operatorname{Val(12)}, \operatorname{Ile}(9), \operatorname{Leu}(16), \operatorname{Trp}(5), \operatorname{Leu}(20)$ and $\operatorname{Met}(1)]$ against the radius of gyration of the peptide over the entire MD trajectory. The purple line is the cut-off distance for the core residues in hydrophobic contact with each other.

Figure S-10. Fluorescence spectrum of the peptide against NATA displaying 4 nm blue shift and a two-fold lower intensity of fluorescence.

Figure S-11. Quenching of the peptide fluorescence by the external quencher KI over the concentration range $0-0.2 \mathrm{M}$.

Figure S-12. Quenching of the NATA fluorescence by the external quencher KI over the concentration range $0-0.2 \mathrm{M}$.

Figure S-13. Stern-Volmer plots of the KI quenching experiments for the peptide and NATA at room temperature. Since the Stern-Volmer plots were deviating from their ideal behavior of linearity a statistical linear fit was generated by Microsoft excel sheet (Windows XP) over all the points for NATA with $R^{2}$ value $=0.97$ and Peptide with $R^{2}$ value $=0.91$ to satisfy the bimolecular quenching equation $\mathrm{I}_{0} / \mathrm{I}=1+\mathrm{K}_{\mathrm{sv}}[\mathrm{Q}]$, where $\mathrm{I}_{0}=$ Fluorescence intensity in the absence of external quencher, $\mathrm{I}=$ Fluorescence intensity in the presence of external quencher, $\mathrm{Q}=$ Concentration of the quencher and $\mathrm{K}_{\mathrm{sv}}$ $=$ Stern-Volmer constant, calculated from the slope of the line.
Figure S-14. Reduction of fluorescence intensity of NATA by free methionine over the concentration ranges $0-0.3 \mathrm{M}$ establishing it as a quencher of tryptophan fluorescence.

Figure S-15. Stern-Volmer plots of the methionine quenching experiments for NATA, illustrating its quenching efficiency as a non-standard quencher against the standard quencher KI.

Figure S-16. The \% burial of $\operatorname{Trp}(5)$ side-chain in the peptide against Gly-Trp-Gly model calculated by NACCESS over the MD trajectory in $\mathrm{H}_{2} \mathrm{O}$ at 300 K .

Table S-1. The chemical shift assignments of the peptide in $\mathrm{H}_{2} \mathrm{O}$ achieved by the combined use of TOCSY and NOESY. The observed sequential cross peaks in NOESY helped in unambiguous assignments of the spin systems

Table S-2. The distance restraints used for structure calculations by DYANA generated from unambiguous NOEs (checked by Distance check module in DYANA) from adjacent and non-adjacent residues in $\mathrm{H}_{2} \mathrm{O}$. 5 van der Waals inter-strand distance constraints were also used for the structure calculations (not shown).

Table S-3. Average values of backbone dihedral angles $(\phi, \psi)$ with standard deviation over 11 structures collected from 50 random structures generated by DYANA simulation and 50 structures collected at an interval of 300 ps over the entire molecular dynamics trajectories in $\mathrm{H}_{2} \mathrm{O}$. The program MolMol was used for superposition and calculation of the dihedrals.
(A)
(B)
(C)


Figure S-1

(B)


Figure S-2

(C)


Figure S-3


Figure S-4


Figure S-5


Figure S-6


Figure S-7


Figure S-8


Figure S-9


Figure S-10


Figure S-11


Figure S-12


Figure S-13


Figure S-14


Figure S-15


Figure S-16

| Amino-acids | NH | $\mathrm{C}^{\alpha} \mathrm{H}$ | $\mathbf{C}^{\beta} \mathbf{H}$ | $\mathbf{C}^{\gamma} \mathbf{H} / \mathbf{C}^{\boldsymbol{\delta}} \mathbf{H}$ | Others |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\operatorname{Met}(1)$ | 8.26 | 4.40 | 1.88, 1.39 | 2.43, 1.96 | 2.50 |
| Thr $(2)$ | 8.21 | 4.35 | 4.27 | 1.81 |  |
| D-Val(3) | 8.72 | 4.36 | 1.61 |  | 0.88 |
| Glu(4) | 8.60 | 4.24 | 1.77 | 2.21 |  |
| Trp(5) | 8.11 | 4.67 | 3.31, 3.20 | 7.24 | $\begin{gathered} \text { 10.10, 7.58, } \\ 7.04,7.18 \\ 7.40 \end{gathered}$ |
| $\operatorname{Ser}(6)$ | 7.98 | 4.38 | 3.72 |  |  |
| D-Ala(7) | 8.17 | 4.44 | 1.11 |  |  |
| $\operatorname{Thr}(8)$ | 8.34 | 4.40 | 4.28 | 1.37 |  |
| $\mathrm{Ile}(9)$ | 8.35 | 4.44 | 2.17 | 1.80, 1.66 | 0.82, 0.81 |
| D-Pro(10) |  | 4.25 | 1.81, 1.65 | 1.43, 1.36 | 2.96 |
| Gly(11) | 7.96 | 4.21, 4.00 |  |  |  |
| $\operatorname{Val}(12)$ | 8.08 | 4.10 | 2.04 |  | 0.90 |
| Ser(13) | 8.33 | 4.60 | 3.81 |  |  |
| D-Val(14) | 7.90 | 4.21 | 2.10 |  | 0.90 |
| Asn(15) | 8.58 | 4.36 | 2.84, 2.68 |  | 7.54, 6.88 |
| Leu(16) | 8.22 | 4.38 | 1.73, 1.64 | 1.54 | 0.89, 0.82 |
| Lys(17) | 8.43 | 4.50 | 2.60, 2.52 | 1.96, 2.10 | 3.80, 7.50 |
| D-Ala(18) | 8.10 | 4.46 | 1.10 |  |  |
| Thr(19) | 8.14 | 4.31 | 4.07 | 1.40 |  |
| Leu(20) | 8.15 | 4.43 | 1.70 | 1.60 | 0.90 |

Table S-1

| NOEs between the residues in H2O | Calculated NOE distance |  |
| :---: | :---: | :---: |
|  |  |  |
| MET HN |  | 1 MET QG |
| 1 MET HN | 19 THR HA | 4.24 |
| 2 THR HA | 5 TRP HE3 | 3.39 |
| 2 THR HA | 5 TRP HZ3 | 4.26 |
| 2 THR HA | 18 ALAD HN | 4.42 |
| 2 THR HB | 20 LEU HN | 2.93 |
| 2 THR HB | 5 TRP HD1 | 2.40 |
| 3 VALD HN | 4 GLU- HA | 5.07 |
| 3 VALD HA | 5 TRP- HZ2 | 3.45 |
| 4 GLU- HA | 16 LEU HN | 4.38 |
| 4 GLU- HA | 18 ALAD HN | 2.40 |
| 4 GLU- QG | 17 LYS+ QG | 3.64 |
| 5 TRP HN | 6 SER QB | 5.98 |
| 5 TRP HA | 16 LEU HN | 4.92 |
| 5 TRP HD1 | 9 SER HB | 4.60 |
| 5 TRP HZ2 | 20 LEU HN | 5.50 |
| 5 TRP HH2 | 19 THR HA | 4.97 |
| 5 TRP HZ2 | 19 THR HA | 3.89 |
| 5 TRP HH2 | 20 LEU HN | 4.23 |
| 6 SER QB | 16 LEU HN | 4.63 |
| 7 ALAD HN | 15 ASN HA | 5.35 |
| 7 ALAD HA | 8 THR HN | 2.46 |
| 7 ALAD QB | 9 ILE HN | 3.14 |
| 7 ALAD QB | 14 VALD HN | 5.78 |
| 8 THR HN | 9 ILE QG1 | 5.10 |
| 8 THR HA | 14 VALD HN | 4.80 |
| 8 THR HB | 14 VALD HN | 3.73 |
| 8 THR QG2 | 14 VALD HN | 3.30 |
| 11 GLY HN | 13 SER QB | 5.75 |
| 12 VAL HB | 13 SER HN | 4.95 |
| 13 SER HN | 14 VALD HN | 3.58 |
| 13 SER HN | 14 VALD HA | 3.30 |
| 13 SER HN | 14 VALD QQG | 2.90 |
| 14 VALD HN | 15 ASN HN | 6.94 |
| 14 VALD HB | 15 ASN HN | 3.48 |
| 15 ASN QB | 16 LEU HN | 4.17 |
| 16 LEU QQD | 20 LEU HG | 4.42 |
| 18 ALAD HA | 19 THR HN | 5.46 |
| 19 THR HB | 20 LEU HN | 2.83 |
| 19 THR QG2 | 20 LEU HN | 3.45 |
|  |  |  |

Table S-2

| Residues | Minimum energy <br> DYANA structure <br> $(\phi, \psi)$ | Average DYANA <br> structure $(\phi, \psi)$ | Average MD structure <br> $(\phi, \psi)$ |
| :---: | :---: | :---: | :---: |
| Met (1) | $\psi=-177.7$ | $\psi=160 \pm 48$ | $\psi=136 \pm 42$ |
| THR (2) | $-60.2,122.5$ | $-141 \pm 49,116 \pm 7$ | $-82 \pm 60,138 \pm 40$ |
| (D) VAL (3) | $161.2,-58.3$ | $162 \pm 3,-65 \pm 14$ | $120 \pm 30,-122 \pm 26$ |
| GLU (4) | $-172.8,111.3$ | $-170 \pm 3,124 \pm 25$ | $-78 \pm 29,89 \pm 82$ |
| TRP (5) | $-100.9,56.0$ | $-110 \pm 21,57 \pm 3$ | $-81 \pm 92,148 \pm 94$ |
| SER (6) | $-63.8,106.4$ | $-59 \pm 4,108 \pm 20$ | $-117 \pm 19,131 \pm 23$ |
| (D) ALA (7) | $163.9,-165.5$ | $160 \pm 9,-162 \pm 6$ | $97 \pm 38,-119 \pm 19$ |
| THR (8) | $-162.6,72.5$ | $-152 \pm 21,68 \pm 7$ | $-99 \pm 26,-43 \pm 44$ |
| ILE (9) | $-112.1,83.3$ | $-104 \pm 17,98 \pm 29$ | $-91 \pm 30,122 \pm 16$ |
| (D) PRO (10) | $\psi=81.4$ | $\psi=62 \pm 67$ | $\psi=-137 \pm 51$ |
| GLY (11) | $131.8,-76.4$ | $152 \pm 39,-75 \pm 78$ | $-90 \pm 47,151 \pm 64$ |
| VAL (12) | $-69.4,160.0$ | $-71 \pm 34,150 \pm 17$ | $-100 \pm 63,37 \pm 73$ |
| SER (13) | $-163.1,54.8$ | $-165 \pm 2,48 \pm 13$ | $-128 \pm 34,119 \pm 32$ |
| (D) VAL (14) | $162.1,-82.0$ | $140 \pm 50,-77 \pm 11$ | $107 \pm 28,-127 \pm 22$ |
| ASN (15) | $-164.5,165.0$ | $-159 \pm 8,165 \pm 0.9$ | $-104 \pm 27,132 \pm 30$ |
| LEU (16) | $-154.2,89.4$ | $-149 \pm 10,106 \pm 40$ | $-105 \pm 55,100 \pm 87$ |
| LYS (17) | $-100.1,101.3$ | $-112 \pm 33,109 \pm 14$ | $-101 \pm 82,128 \pm 35$ |
| (D) ALA (18) | $157.1,-161.8$ | $162 \pm 2,-157 \pm 11$ | $99 \pm 27,-126 \pm 24$ |
| THR (19) | $-74.3,138.1$ | $-100 \pm 22,142 \pm 7$ | $-86 \pm 30,92 \pm 77$ |
| LEU (20) | $\phi=-60.1$ | $\phi=-140 \pm 31$ | $\phi=-112 \pm 48$ |
|  |  |  |  |

Table S-3

